FDA-cleared tool could assist in diagnosing autism

The EarliPoint Evaluation has demonstrated positive phase 3 trial results, aiding in autism diagnosis and assessment in children aged 16 to 30 months. Warren Jones, PhD, chief scientific officer and cofounder of EarliTec Diagnostics, Inc., discusses the eye-tracking tool, how it is currently being used, and what could be in store for the future.


  • No comments yet.
  • Add a comment